What Genkyotex does

Genkyotex is a clinical-stage biopharmaceutical company that develops small-molecule inhibitors of NOX enzymes, the family of enzymes responsible for producing oxygen radicals implicated in fibrotic disease. Founded in 2006 and based in Geneva, Switzerland, the company's lead asset is setanaxib, a NOX enzyme inhibitor positioned as a 'pipeline in a product' for fibrotic rare diseases and solid tumors across four indications: Primary Biliary Cholangitis (PBC), Idiopathic Pulmonary Fibrosis (IPF), Alport Syndrome, and Solid Tumors (SCCHN). The asset has been administered to more than 320 subjects across completed Phase 1 and Phase 2 clinical trials, building an extensive safety dataset.

The business has secured Orphan Drug Designation from both the FDA and EMA for setanaxib in PBC, IPF, and Alport Syndrome, and Fast Track Designation from the FDA for PBC, with global rights to the asset held by the Calliditas Therapeutics AB entity that has become the corporate successor. The solid tumor (SCCHN) indication is positioned for out-licensing, while rare-disease indications are being advanced through ongoing Phase 2b (PBC), investigator-led Phase 2 (IPF), and Phase 2 proof-of-concept (Alport) trials, with multiple data readouts scheduled across 2024 and 2025. The company has financed development through at least eight funding rounds since inception, including a Series C of roughly $25.6M in 2012, and acquired Genticel in February 2017 to expand its pipeline.

As a pre-revenue clinical-stage developer, Genkyotex has no commercial product, no disclosed paying customers, and no disclosed pricing or revenue mechanics. Future revenue, if and when setanaxib is approved, would flow through regulatory-approved commercial channels for rare-disease therapeutics, and potentially through a licensing partner for the SCCHN oncology indication. The current business model is therefore defined by capital-intensive clinical development, regulatory designation accumulation, and pending clinical de-risking events rather than product sales.

Name

Genkyotex

Legal name

Calliditas Therapeutics AB

Website

https://genkyotex.com

Company type

Private

Founded year

2006

Operating status

Operating

Headcount range

11–50 employees

Short description

Genkyotex is a clinical-stage biopharmaceutical company developing setanaxib, a NOX enzyme inhibitor for fibrotic rare diseases (PBC, IPF, Alport Syndrome) and solid tumors, holding global rights and multiple FDA/EMA orphan drug designations.

Ownership category

akta.pro rank

Product category

Clinical-stage biopharmaceuticals

NAICS

Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Rare Pediatric & Congenital Disorder Therapies (HLAIAIAN)

Keywords

• NOX enzyme inhibitors
• Fibrosis drug development
• Rare disease therapeutics
• Clinical stage biopharmaceutical
• Orphan drug development

Headquarters

HQ city

Geneva

HQ country

Switzerland

HQ region

Europe

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Distribution channels1 record

Marketing channels1 record

Core offering

Genkyotex develops Setanaxib, a NOX enzyme inhibitor being developed as a clinical-stage pipeline product for fibrotic rare diseases and solid tumors. The compound is being advanced across multiple indications including Primary Biliary Cholangitis (PBC), Idiopathic Pulmonary Fibrosis (IPF), Alport Syndrome, and Solid Tumors (SCCHN), with global rights held across all indications.

Differentiator

Problem solved

Functional benefit

Products and services

• Setanaxib

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Scale indicators1 record

Recent moves6 records

Expansion highlights4 records

Direct peers

• Pliant Therapeutics: Pliant is a clinical-stage fibrosis biotech with bexotegrast (Phase 2b/3 in IPF) targeting exactly the same indications as setanaxib. Both companies apply novel mechanisms to fibrotic rare diseases with similar regulatory strategies (ODD pursuit) and similar stages of clinical development.
• Madrigal Pharmaceuticals: Madrigal's resmetirom (Rezdiffra) is the first FDA-approved therapy for MASH liver fibrosis, demonstrating commercial viability of fibrosis-targeted therapies in liver disease. Highly comparable to setanaxib's liver-fibrosis (PBC) positioning on patient population, prescriber base, and regulatory pathway.
• Intercept Pharmaceuticals: Intercept's Ocaliva (obeticholic acid) is the leading approved second-line therapy for Primary Biliary Cholangitis — the same lead indication Genkyotex's setanaxib targets. As the only direct head-to-head competitor in PBC, Intercept is the closest comparable on commercial economics, regulatory positioning, and patient population overlap.
• Inventiva: Inventiva's lead asset lanifibranor is in development for MASH and previously for PBC, giving it near-direct overlap with setanaxib's fibrosis / rare-disease liver strategy. Both are clinical-stage European-headquartered small-molecule fibrosis biotechs with comparable size and capital structure.
• FibroGen: FibroGen's pamrevlumab targets IPF and other fibrotic indications (Duchenne muscular dystrophy, pancreatic cancer), creating direct overlap with setanaxib's fibrosis pipeline. Comparable in mechanism novelty, ODD pursuit, and target-patient focus despite FibroGen being broader in scope.
• CymaBay Therapeutics (Gilead): CymaBay's seladelpar (now FDA-approved as Livdelzi) is a direct PBC competitor targeting second-line PBC patients — the same clinical positioning setanaxib is pursuing. Its acquisition by Gilead for ~$4.3B is a useful reference point for the strategic value of a successful PBC pipeline asset.

Emerging players

• Galapagos NV: Galapagos developed ziritaxestat and other IPF/fibrosis assets, directly overlapping with setanaxib's fibrosis pipeline. While it terminated some programs post-2022 setbacks, its fibrosis R&D focus and European clinical-stage footprint make it a structurally comparable peer in the rare-disease fibrosis arena.

Broad incumbents

• Roche / Genentech: Roche's Esbriet (pirfenidone) is — together with OFEV — one of two approved IPF therapies and an unavoidable incumbent in any IPF commercial strategy. Roche's fibrosis portfolio also extends into additional fibrotic indications, making it the widest competitor to setanaxib's fibrosis positioning.
• Boehringer Ingelheim: Boehringer's OFEV (nintedanib) is the standard-of-care therapy in IPF — the same indication setanaxib is targeting. As the entrenched incumbent with established formulary access and physician familiarity, BI defines the competitive landscape setanaxib must enter and represents the gold-standard benchmark for any new IPF readout.

Others

• Calliditas Therapeutics AB: Calliditas is the acquirer/integrator that has acquired or is acquiring Genkyotex per the recommended offer on calliditas.se, and now controls setanaxib's global rights. While Calliditas is the parent corporate entity, its approved TARPEYO franchise and IgA nephropathy focus sit adjacent to setanaxib's rare-disease scope rather than in direct competition.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

• Xx.com/genkyotex_off
• LinkedInlinkedin.com/company/genkyotex-s.a

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds8 records

Investors10 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Genkyotex